Share：
Share this content in WeChat
X
[Chinese][PDF]2324
• Clinlcal Guidelines & Expert Consensus •
Chinese expert consensus on the evaluation of abdominal immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI
Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association
MRI Group of Chinese Society of Radiology Chinese Medical Association
Abdominal Group of Chinese Society of Radiology Chinese Medical Association
Editorial Board of Chinese Journal of Magnetic Resonance Imaging

Cite this article as: Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association, MRI Group of Chinese Society of Radiology Chinese Medical Association, Abdominal Group of Chinese Society of Radiology Chinese Medical Association, et al. Chinese expert consensus on the evaluation of abdominal immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI[J]. Chin J Magn Reson Imaging, 2024, 15(12): 28-37. DOI:10.12015/issn.1674-8034.2024.12.004.


[Abstract] The advent of Immune checkpoint inhibitors (ICIs) has heralded a new era in the immunotherapy of malignant tumors. Despite this, the accompanying immune-related adverse events (irAEs) have become a major challenge in the treatment process. Among them, the abdomen is the most common site for irAEs to occur, and abdominal irAEs are also the most common reason for the discontinuation of immunotherapy. MRI plays a key role in detecting and evaluating abdominal irAEs. Therefore, early diagnosis and assessment of abdominal irAEs through MRI is crucial. However, there is currently a lack of standardized consensus on MRI examination and diagnosis of abdominal irAEs caused by ICIs in China. To this end, the Molecular Imaging Group, Abdominal Group, and Magnetic Resonance Group of the Radiology Branch of the Chinese Medical Association, as well as the Editorial Board of Chinese Journal of Magnetic Resonance Imaging are committed to formulating a consensus on MRI scanning protocols and diagnostic reporting for abdominal irAEs caused by ICIs. This committee has reached this consensus based on literature, expert experience, and internal discussions among committee members. The consensus aims to standardize the application of MRI in tumor immunotherapy, optimize the assessment of abdominal irAEs, and provide a solid imaging basis for clinical practice.
[Keywords] magnetic resonance imaging；immune checkpoint inhibitors；abdominal immune-related adverse events；clinical application；expert consensus

Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association   MRI Group of Chinese Society of Radiology Chinese Medical Association   Abdominal Group of Chinese Society of Radiology Chinese Medical Association   Editorial Board of Chinese Journal of Magnetic Resonance Imaging  

Corresponding author: SUN H Z (Department of Radiology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China), E-mail: sunhongzan@126.com JU S H (Department of Radiology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China), E-mail: jsh@seu.edu.cn

Conflicts of interest   None.

Received  2024-10-01
Accepted  2024-12-10
DOI: 10.12015/issn.1674-8034.2024.12.004
Cite this article as: Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association, MRI Group of Chinese Society of Radiology Chinese Medical Association, Abdominal Group of Chinese Society of Radiology Chinese Medical Association, et al. Chinese expert consensus on the evaluation of abdominal immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI[J]. Chin J Magn Reson Imaging, 2024, 15(12): 28-37. DOI:10.12015/issn.1674-8034.2024.12.004.

[1]
BAGCHI S, YUAN R, ENGLEMAN E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249. DOI: 10.1146/annurev-pathol-042020-042741.
[2]
TWOMEY J D, ZHANG B L. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics[J/OL]. AAPS J, 2021, 23(2): 39 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/33677681/. DOI: 10.1208/s12248-021-00574-0.
[3]
HASLAM A, GILL J, PRASAD V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs[J/OL]. JAMA Netw Open, 2020, 3(3): e200423 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/32150268/. DOI: 10.1001/jamanetworkopen.2020.0423.
[4]
BAXI S, YANG A N, GENNARELLI R L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J/OL]. BMJ, 2018, 360: k793 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/29540345/. DOI: 10.1136/bmj.k793.
[5]
KHOJA L, DAY D, WEI-WU CHEN T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review[J]. Ann Oncol, 2017, 28(10): 2377-2385. DOI: 10.1093/annonc/mdx286.
[6]
RAMOS-CASALS M, BRAHMER J R, CALLAHAN M K, et al. Immune-related adverse events of checkpoint inhibitors[J/OL]. Nat Rev Dis Primers, 2020, 6(1): 38 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/32382051/. DOI: 10.1038/s41572-020-0160-6.
[7]
ALESSANDRINO F, SAHU S, NISHINO M, et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor[J]. Abdom Radiol, 2019, 44(5): 1917-1927. DOI: 10.1007/s00261-019-01935-2.
[8]
WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923.
[9]
BERZ A M, BOUGHDAD S, VIETTI-VIOLI N, et al. Imaging assessment of toxicity related to immune checkpoint inhibitors[J/OL]. Front Immunol, 2023, 14: 1133207 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/36911692/. DOI: 10.3389/fimmu.2023.1133207.
[10]
CUNNINGHAM M, GUPTA R, BUTLER M. Checkpoint inhibitor hepatotoxicity: pathogenesis and management[J]. Hepatology, 2024, 79(1): 198-212. DOI: 10.1097/HEP.0000000000000045.
[11]
HAANEN J, OBEID M, SPAIN L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(12): 1217-1238. DOI: 10.1016/j.annonc.2022.10.001.
[12]
SANGRO B, CHAN S L, MEYER T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 320-341. DOI: 10.1016/j.jhep.2019.10.021.
[13]
OGAWA K, KAMIMURA K, TERAI S. Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis[J]. Hepatology, 2019, 69(2): 914-916. DOI: 10.1002/hep.30189.
[14]
PI B R, WANG J, TONG Y F, et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management[J/OL]. Eur J Gastroenterol Hepatol, 2021, 33(1SSuppl 1): e858-e867 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/34482313/. DOI: 10.1097/MEG.0000000000002280.
[15]
KASHIMA J, OKUMA Y, SHIMIZUGUCHI R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report[J]. Cancer Immunol Immunother, 2018, 67(1): 61-65. DOI: 10.1007/s00262-017-2062-3.
[16]
MIZUNO K, ITO T, ISHIGAMI M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies[J]. J Gastroenterol, 2020, 55(6): 653-661. DOI: 10.1007/s00535-020-01677-9.
[17]
CHEUNG V, GUPTA T, PAYNE M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre[J]. Frontline Gastroenterol, 2019, 10(4): 364-371. DOI: 10.1136/flgastro-2018-101146.
[18]
OKAMOTO K, HIJIOKA S, NAGASHIO Y, et al. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments[J]. Jpn J Clin Oncol, 2024, 54(8): 887-894. DOI: 10.1093/jjco/hyae060.
[19]
ONOYAMA T, TAKEDA Y, YAMASHITA T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review[J]. World J Gastroenterol, 2020, 26(3): 353-365. DOI: 10.3748/wjg.v26.i3.353.
[20]
GOSANGI B, MCINTOSH L, KERALIYA A, et al. Imaging features of toxicities associated with immune checkpoint inhibitors[J/OL]. Eur J Radiol Open, 2022, 9: 100434 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/35967881/. DOI: 10.1016/j.ejro.2022.100434.
[21]
ANDERSON M A, KURRA V, BRADLEY W, et al. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography[J/OL]. Br J Radiol, 2021, 94(1118): 20200663 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/33112648/. DOI: 10.1259/bjr.20200663.
[22]
MEKKI A, DERCLE L, LICHTENSTEIN P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1[J]. Eur J Cancer, 2018, 96: 91-104. DOI: 10.1016/j.ejca.2018.03.006.
[23]
CHU D, ADLER D G. Malignant biliary tract obstruction: evaluation and therapy[J]. J Natl Compr Canc Netw, 2010, 8(9): 1033-1044. DOI: 10.6004/jnccn.2010.0075.
[24]
KATABATHINA V S, DASYAM A K, DASYAM N, et al. Adult bile duct strictures: role of MR imaging and MR cholangiopancreatography in characterization[J]. Radiographics, 2014, 34(3): 565-586. DOI: 10.1148/rg.343125211.
[25]
TAKINAMI M, ONO A, MORIGUCHI M, et al. Pembrolizumab-related sclerosing cholangitis manifested by a pruned-tree appearance of the bile ducts[J]. Jpn J Clin Oncol, 2021, 51(4): 666-667. DOI: 10.1093/jjco/hyaa201.
[26]
DOHERTY G J, DUCKWORTH A M, DAVIES S E, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury[J/OL]. ESMO Open, 2017, 2(4): e000268 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/29081991/. DOI: 10.1136/esmoopen-2017-000268.
[27]
WILLIAMS H, AITCHISON R. Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis[J/OL]. BMJ Case Rep, 2019, 12(12): e232505 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/31811095/. DOI: 10.1136/bcr-2019-232505.
[28]
Abdominal Group of Chinese Society of Radiology Chinese Medical Association. Chinese expert consensus of scanning protocol and clinical application of magnetic resonance cholangiopancreatography[J]. Chin J Magn Reson Imag, 2023, 14(4): 1-5, 21. DOI: 10.12015/issn.1674-8034.2023.04.001.
[29]
HOU Y C, ZHAO H Q, DONG C E, et al. Research advances in immune checkpoint inhibitor-related cholangitis[J]. J Clin Hepatol, 2023, 39(2): 463-468. DOI: 10.3969/j.issn.1001-5256.2023.02.034.
[30]
EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines: management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.
[31]
COHEN J V, DOUGAN M, ZUBIRI L, et al. Liver biopsy findings in patients on immune checkpoint inhibitors[J]. Mod Pathol, 2021, 34(2): 426-437. DOI: 10.1038/s41379-020-00653-1.
[32]
LIM J H. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings[J]. AJR Am J Roentgenol, 2003, 181(3): 819-827. DOI: 10.2214/ajr.181.3.1810819.
[33]
MOON S G, HAN J K, KIM T K, et al. Biliary obstruction in metastatic disease: thin-section helical CT findings[J]. Abdom Imaging, 2003, 28(1): 45-52. DOI: 10.1007/s00261-001-0191-8.
[34]
VON FIGURA G, STEPHANI J, WAGNER M, et al. Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel[J/OL]. Endoscopy, 2009, 41(Suppl 2): E153-E154 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/19544276/. DOI: 10.1055/s-0029-1214707.
[35]
MICHOT J M, RAGOU P, CARBONNEL F, et al. Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: a brief communication[J]. J Immunother, 2018, 41(2): 84-85. DOI: 10.1097/CJI.0000000000000202.
[36]
ZHAO Z, ZHANG W K, PANG L B, et al. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis[J/OL]. Front Immunol, 2023, 14: 1166299 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/37359551/. DOI: 10.3389/fimmu.2023.1166299.
[37]
THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012.
[38]
ABU-SBEIH H, TANG T L, LU Y, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury[J/OL]. J Immunother Cancer, 2019, 7(1): 31 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/30728076/. DOI: 10.1186/s40425-019-0502-7.
[39]
NAKANO R, SHIOMI H, FUJIWARA A, et al. Clinical characteristics of ICI-related pancreatitis and cholangitis including radiographic and endoscopic findings[J/OL]. Healthcare, 2022, 10(5): 763 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/35627900/. DOI: 10.3390/healthcare10050763.
[40]
TAN B, CHEN M J, GUO Q, et al. Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events[J]. Thorac Cancer, 2021, 12(12): 1814-1823. DOI: 10.1111/1759-7714.13990.
[41]
HELLER M T, HARISINGHANI M, NEITLICH J D, et al. Managing incidental findings on abdominal and pelvic CT and MRI, part 3: white paper of the ACR Incidental Findings Committee II on splenic and nodal findings[J]. J Am Coll Radiol, 2013, 10(11): 833-839. DOI: 10.1016/j.jacr.2013.05.020.
[42]
BUSIREDDY K K, ALOBAIDY M, RAMALHO M, et al. Pancreatitis-imaging approach[J]. World J Gastrointest Pathophysiol, 2014, 5(3): 252-270. DOI: 10.4291/wjgp.v5.i3.252.
[43]
NEGRELLI R, MANFREDI R, PEDRINOLLA B, et al. Pancreatic duct abnormalities in focal autoimmune pancreatitis: MR/MRCP imaging findings[J]. Eur Radiol, 2015, 25(2): 359-367. DOI: 10.1007/s00330-014-3371-y.
[44]
LEE S, KIM J H, KIM S Y, et al. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma[J]. Eur Radiol, 2018, 28(12): 5267-5274. DOI: 10.1007/s00330-018-5565-1.
[45]
SHI W, TAN B, LI Y, et al. The diagnosis of immune-related pancreatitis disguised as multifocal lesions on MRI by endoscopic ultrasound-guided fine-needle biopsy: a case report[J/OL]. Front Immunol, 2022, 13: 933595 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/36177047/. DOI: 10.3389/fimmu.2022.933595.
[46]
ZHU L, ZHANG W, JIN Z Y, et al. DWI of autoimmune pancreatitis: is it an imaging biomarker for disease activity?[J]. AJR Am J Roentgenol, 2021, 216(5): 1240-1246. DOI: 10.2214/AJR.20.23368.
[47]
ROGERS B B, CUDDAHY T, ZAWISLAK C. Management of acute pancreatitis associated with checkpoint inhibitors[J]. J Adv Pract Oncol, 2020, 11(1): 49-62. DOI: 10.6004/jadpro.2020.11.1.3.
[48]
LUMLERTGUL N, VASSALLO P, TYDEMAN F, et al. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study[J/OL]. Eur J Cancer, 2023, 191: 112967 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/37499561/. DOI: 10.1016/j.ejca.2023.112967.
[49]
BECK K E, BLANSFIELD J A, TRAN K Q, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4[J]. J Clin Oncol, 2006, 24(15): 2283-2289. DOI: 10.1200/JCO.2005.04.5716.
[50]
MOK T S K, WU Y L, KUDABA I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830. DOI: 10.1016/S0140-6736(18)32409-7.
[51]
ROBERT C, SCHACHTER J, LONG G V, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26): 2521-2532. DOI: 10.1056/NEJMoa1503093.
[52]
WEBER J S, KÄHLER K C, HAUSCHILD A. Management of immune-related adverse events and kinetics of response with ipilimumab[J]. J Clin Oncol, 2012, 30(21): 2691-2697. DOI: 10.1200/JCO.2012.41.6750.
[53]
WANG Y H, ABU-SBEIH H, MAO E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson[J/OL]. J Immunother Cancer, 2018, 6(1): 37 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/29747688/. DOI: 10.1186/s40425-018-0346-6.
[54]
CHAPUT N, LEPAGE P, COUTZAC C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J/OL]. Ann Oncol, 2019, 30(12): 2012 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/28368458/. DOI: 10.1093/annonc/mdz224.
[55]
GROVER S, DOUGAN M, TYAN K, et al. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis[J]. Cancer, 2020, 126(16): 3758-3767. DOI: 10.1002/cncr.32966.
[56]
BRUINING D H, ZIMMERMANN E M, LOFTUS E V, et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn's disease[J]. Radiology, 2018, 286(3): 776-799. DOI: 10.1148/radiol.2018171737.
[57]
ZHOU Z L, HU D Y, SHEN Y Q. An interpretation of the first joint statement (2017) of ESGAR and ESPR regarding the technique performance of small bowel and colon imaging[J]. Radiol Pract, 2018, 33(8): 773-779. DOI: 10.13609/j.cnki.1000-0313.2018.08.001.

PREV Chinese expert consensus on MRI evaluation of endocrine system immune-related adverse events induced by immune checkpoint inhibitors in malignant tumors
NEXT Clinical application advantages, challenges, and future prospects of 7 T MRI
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn